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A library of dimeric CD1d ligands, containing two a-galactosyl ceramide (a-GalCer) units linked by
spacers of varying lengths has been synthesised. The key dimerisation reactions were carried out via
copper-catalysed click reactions between a 600-azido-600-deoxy-a-galactosyl ceramide derivative and var-
ious diynes. Each a-GalCer dimer was tested for its ability to stimulate iNKT cells.
 2012 Elsevier Ltd. Open access under CC BY license.1. Introduction
A multimeric version of a monomeric ligand can achieve higher
afﬁnity and speciﬁcity for a target receptor.1–3 As a result, incorpo-
rating multiple copies of an active pharmacophore within a single
molecule can increase biological activity by several orders of mag-
nitude. These observations have opened up the development of so-
called multivalent drug candidates as an active area of research.4,5
There are now numerous examples of synthetic homodimers,
which represent the simplest form of a multivalent compound,
exhibiting signiﬁcantly improved potency over their monomeric
counterparts.6–11 For example, dimeric derivative 2 of zanamivir
(1), an inﬂuenza virus neuraminidase inhibitor, was found to be
100-fold more potent an inhibitor of inﬂuenza virus replication,
both in vitro and in vivo, than its monomer analogue.6 In a second
example, certain dimeric versions (including 4) of the DNA interca-
lator N-[(2-dimethylamino)ethyl]acridine (DACA, 3) displayed ﬁve
times the cytotoxic potency of the parent monomer.12,13 In other
cases, the dimeric molecule exhibits different properties entirely
from the corresponding monomer. For example, artemisinin (5) is
an antimalarial agent, whilst its homodimeric analogues 6a–c
exhibit potent anti-tumour activity (Fig. 1).14Y license. As part of a wider research programme into the development of
novel CD1d ligands,15–18 we targeted a series of dimeric analogues
of the prototypical invariant natural killer T (iNKT) cell agonist, a-
galactosyl ceramide (a-GalCer, KRN7000 (7), Figure 2). a-GalCer19
7 is a synthetic glycolipid, which binds to the non-polymorphic
MHC-class-I-like molecule, CD1d. The resulting glycolipid–CD1d
complex is recognised by T cell receptors (TCRs) located on the sur-
face of iNKT cells. Following recognition of the a-GalCer–CD1d
complex, iNKT cells rapidly release a diverse array of both pro-
inﬂammatory (Th1) and regulatory (Th2) cytokines and initiate a
potent immune response. This method of activating the immune
system is currently being explored as a mechanism for ‘boosting’
current vaccination strategies.20–32
Localised clustering of CD1d molecules has been shown to play
an important role in antigen presentation. Park et al. have shown
that lipid rafts are essential for efﬁcient TCR recognition of
CD1d,33 whilst Im et al. have reported that a-GalCer 7 requires
intracellular loading on to CD1d molecules, which leads to the
organised transport of a-GalCer–CD1d complexes into choles-
terol-rich lipid rafts.34 This localisation of CD1d molecules in mem-
brane rafts serves to concentrate CD1d–lipid complexes in the
plasma membrane.35 We hypothesised that bivalent ligands of
the a-GalCer pharmacophore might serve to stabilise these lipid
rafts by forming a cross-linked matrix within the raft structure.
This, in turn, might result in more stable CD1d–glycolipid com-
plexes as a result of a chelating effect.36–38 With an appropriate lin-
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Scheme 1. Proposed synthesis of a-GalCer homodimers.
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Scheme 2. Synthesis of triazole-containing a-GalCer monomers.
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different, biological activity compared with their natural monomeric counterparts.
O
O
NH
OH
OH
HO
HO
HO
OH
O
13
24
7
Figure 2. The prototypical iNKT cell agonist KRN7000 (a-GalCer) 7.
P. J. Jervis et al. / Carbohydrate Research 356 (2012) 152–162 153ker separating the two a-GalCer units, the dimer might be able to
bind two CD1d molecules whilst still allowing space for presenta-
tion to iNKT TCRs.39,40 The length of the linking unit in such ligands
would be of key importance for optimal divalent binding; too long
and it might provide too large a containment volume for the sec-
ond pharmacophore and would result in the two a-GalCer moieties
effectively behaving as unconnected entities; too short,41,42 and
steric hindrance might block the approach of a second CD1d mol-
ecule, although in this case, enhanced binding might still be ob-
served as the result of a statistical re-binding effect.10 In the
event that a dimer with a shorter linker is able to bind two CD1d
molecules, the presence of a second a-GalCer–CD1d complex in
close proximity might still serve to block the approach of the
TCR.39,40 In this way, a dimer could function as an antagonist and
yet has signal transduction applications.11,43 We now report the
synthesis and initial biological results of a range of homodimers
of a-GalCer, which vary in both the length and type of linker unit.
2. Design and synthesis
Our ﬁrst consideration in the design of bivalent CD1d ligands
was the selection of an appropriate position from which to appenda linker to the a-GalCer molecule. The crystal structure of the
CD1d–glycolipid–iNKT TCR complex39,40 reveals that the 2-, 3-
and 4-hydroxyl groups of the sugar head group are all involved
in hydrogen bonding to either the CD1d molecule or iNKT TCR;
modifying these positions leads to reduced, or even complete loss,
of activity.44–46 In contrast, it has been shown that the iNKT TCR–
glycolipid–CD1d interaction can tolerate derivatisation at C6 of
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154 P. J. Jervis et al. / Carbohydrate Research 356 (2012) 152–162the galactose unit and there are a number of biologically active
CD1d agonists where the 6-hydroxyl group of the sugar has been
replaced with another functional group.47–50 These results are sup-
ported by the crystal structure of the CD1d–a-GalCer complex39
and a crystal structure of a TCR–a-GalCer–CD1d complex,40 which
reveal that the 6-OH of the a-GalCer sugar head group is not di-
rectly involved in hydrogen bonding to either the CD1d molecule
or the iNKT TCR. For these reasons, we selected the 6-position of
the sugar head group as the most suitable site through which to
link together our a-GalCer monomer units.
We have recently developed a facile route to 600-azido-600-
deoxy-a-galactosyl ceramide 8,51 which we considered a potential
advanced intermediate for building a-GalCer dimers. We have
shown that the azido moiety of 8 can serve as a masked amine,
allowing further elaboration to amides, carbamates and ureas;
however more directly, the 600-azido group is also primed for click
chemistry. We therefore postulated that a series of 1,2,3-triazole
derivatives would be readily available through a simple Huisgen
reaction with an appropriate alkyne.52–54 We envisaged that a-Gal-
Cer dimers could be accessed in a single step via a ‘double click’
reaction between 2 equiv of azide 8 and an appropriate diyne
(Scheme 1). This approach would also deliver symmetrical homo-
dimers, which would simplify characterisation and analysis.
Poly(ethylene glycol) spacers were chosen to link the a-GalCer
units together. These units offer compatibility with biological envi-
ronments55 as well as increased solubility of the amphiphilic gly-
colipid units in both aqueous and organic solvents.56,57 We also
chose to investigate alkylene linkers as a hydrophobic comparison.Figure 3. Distances between pharmacophores of target a-GalCer dimers 13a–e and
14a–c.Alkyne-terminated versions of these two types of linkers are read-
ily accessible and would allow the systematic variation of linker
lengths.
In order to test the tolerance of the CD1d–glycolipid–iNKT TCR
complex to these types of linker units, monomeric a-GalCer ana-
logues 10b and 12were ﬁrst synthesised from azide 8 from alkynes
9b and 11, respectively (Scheme 2), and incubated with spleno-
cytes from wildtype C57 BL/6 mice. The presence of IFNc was then
determined by ELISA as previously described by Reddy et al.58
Pleasingly, triazole 10b was found to stimulate iNKT cells in vitro
at similar levels to a-GalCer 7, whilst triazole 12 stimulated iNKT
cells, albeit to a lesser extent (Fig. 5, vide infra).
With the knowledge that the CD1d–glycolipid–iNKT TCR inter-
action tolerated this type of C6 derivatisation, our next consider-
ation was the length of the spacer units to be employed in our
dimer syntheses. Major histocompatibility complex (MHC) mole-
cules, which present peptide fragments to T-cells, are structurally
similar to CD1d molecules, and in a related study, Cebecauer et
al. have studied MHC–peptide dimers.59 Dimers containing short
linkers, 10–30 Å in length, efﬁciently triggered intracellular cal-
cium mobilisation and phosphorylation in cloned cytotoxic T lym-
phocytes, whereas dimers with longer linkers did not. The fact that
MHC–peptide dimers containing linkers as short as 10 Å could still
interact with the TCR raised the question of how the two MHC mol-
ecules align themselves. The authors describe a dimeric binding
model in which two TCRs engage with their a3 domains in an
anti-parallel manner, two MHC–peptide complexes facing each
other. Models of adjacent MHC molecules revealed distances varying
from 12 Å to 46 Å between the a3 domains.59 Applying similar ori-
entations to CD1d models (Fig. 3, top), we proposed a range of a-Gal-
Cer dimers where the lengths of the spacer units separating the
glycolipid pharmacophores could be systematically varied across a
similar range. More speciﬁcally, we targeted a-GalCer dimers 13a–
e and 14a–c, in which the fully extended linker lengths range from
9 Å (for 13a) to 38 Å (for 13e), as estimated from models using
Pro-DRG server (Fig. 3, bottom).
We ﬁrst required our series of diynes. Dipropargyl ether 16a is
available commercially, whilst bis-propargylated di-, tri-, penta-
and octa(ethylene glycol)s 16b–e, respectively, were prepared in
good yield by double deprotonation of the appropriate diol 15a–
d with an excess of sodium hydride, followed by addition of an ex-
cess of propargyl bromide in the presence of tetrabutylammonium
iodide (TBAI). For the alkylene diyne precursors, 1,7-octadiyne
(18a) is commercially available, whilst 1,15-hexadecadiyne (18b)
and 1,21-docosadiyne (18c) were synthesised in moderate yields
by treating 1,12-dibromododecane (17a) and 1,18-dibromooctade- Quoted lengths refer to the linker in its fully extended conformation.
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lenediamine (EDA) complex (Scheme 3).Figure 4. In vitro activation of iNKT cells by dimers 14a–c and 13a–e. Splenocytes from
(14a–c, panel A; 13a–e, panel B). The supernatants were analysed for the presence of IFDiynes 16a–e and 18a–c were next employed in click reactions
with azide 8. Thus, two equivalents of azide 8 and one equivalent
of diyne 16a–e or 18a–c were heated in the presence of copper(II)
sulfate and sodium ascorbate, to provide bis-triazole dimers 13a–e
and 14a–c, respectively, in excellent yields (Scheme 4). These com-
pounds were then tested for their ability to stimulate iNKT cells.
3. Biological results
All of the a-GalCer dimers were found to be active following
incubation with splenocytes from wildtype C57 BL/6 mice (
Fig. 4);58 PEG-linked dimers 13a–e stimulated iNKT cells in vitro
at similar levels to a-GalCer 7 at high concentrations (>10 nM),
although there was no obvious sensitivity to linker length. At lower
concentrations (<1 nM), dimers 13a and 13b, both of which pos-
sess short linkers between the a-GalCer residues, were less active
than dimers 13c–e, which contain longer linkers. Alkylene-linked
dimers 14a–c also stimulated iNKT cells in vitro, but to a lesser ex-
tent than a-GalCer 7. No detectable IFNcwas observed when com-
pounds 13a–e and 14a–c were incubated with splenocytes from
CD1d/ (iNKT cell-deﬁcient) mice (data not shown), indicating
that the observed iNKT cell stimulation by our a-GalCer dimers
is CD1d-dependent.
In order to test the ability of the iNKT TCR to recognise the
CD1d–glycolipid complex, in vitro binding experiments were per-
formed (Fig. 6).60 Dimers 13c–e were comparable to a-GalCer 7
at high concentrations (>10 nM), whilst dimers 13a,b again proved
to be considerably weaker than a-GalCer 7. At lower concentra-
tions (<5 nM), dimers 13c–e, which contain the longer linker units,
displayed greater iNKT-cell recognition than a-GalCer 7. Dimer
13d, which contains a penta(ethylene glycol) linker (26–27 Å
fully extended length), proved optimal. Alkylene-linked dimers
14a–c showed weaker CD1d binding than a-GalCer 7 (Fig. 6) and
we tentatively postulate that the lower activity of this series of di-
mers might be a result of the hydrophobic alkylene linker coiling to
minimise contact with the aqueous medium. This coiling will serve
to decrease the effective length of the linker and may account for
the observed activity of these dimers more closely resembling that
observed for the ethylene glycol dimers containing shorter linkers
(i.e., 13a,b).
In order to investigate whether or not the trends observed with
dimers 13a–e were a consequence of the presence of the second
pharmacophore or due to the presence of the linker unit alone,
we targeted a series of monomers 10a–e each containing a PEG tail
length which corresponded to the same linker lengths separating
the a-GalCer residues in dimers 13a–e. Monomers 10a–e wereC57 BL/6 mice were cultured in the presence of various concentrations of lipids
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Figure 5. In vitro activation of iNKT cells by monomers 12 and 10a–e. Splenocytes from C57 BL/6 mice were cultured in the presence of various concentrations of lipids (12,
panel A; 10a–e, panel B). The supernatants were analysed for the presence of IFNc by ELISA following 48 h of culture.58
Figure 6. iNKT cell recognition of 14a–c and 13a–e. The recognition of 14a–c (panel A) and 13a–e (panel B) by human iNKT TCR tetramer was assessed by ﬂow cytometry
following co-incubation of ﬂuorescent human iNKT cell TCR and hCD1d C1R cells loaded with the indicated lipids.60 MFI = Median Fluorescent Intensity.
156 P. J. Jervis et al. / Carbohydrate Research 356 (2012) 152–162readily accessed via click reactions between azide 8 and alkynes
9a–e. Alkyne 9a was available commercially, whilst alkynes 9b–e
were readily synthesised from alcohols 19a–d (Scheme 5).
Each of the monomers 10a–e was tested for its ability to stim-
ulate iNKT cells (Fig. 5). a-GalCer 7 served as a reference com-
pound, enabling us to compare the data for monomers 10a–e
with the data for the corresponding dimers 13a–e. At high concen-
trations (>10 nM), the level of iNKT-cell stimulation for all of the
monomers 10a–e was not signiﬁcantly different to that observed
for the corresponding dimers (relative to a-GalCer 7 reference).
Surprisingly, at lower concentrations (<1 nM), monomer 10d
proved to be a more potent activator of iNKT cells than its dimeric
equivalent (13d), relative to a-GalCer 7, whilst 10a, the control for
13a, was again inactive at low concentrations in vitro. The fact thatdimers 13a–e do not show any enhanced biological activity over
their corresponding monomers 10a–e suggests that a bivalent ef-
fect is not taking place in vitro. A comparison of the data for mono-
mer 12, containing an octyl chain, and the alkylene-linked dimers
14a–c also provides little evidence for a bivalent effect.
The effect of lipid rafts and clustering effects on iNKT-cell acti-
vation might be expected to be more apparent in vivo,61 and the
in vivo results were indeed more interesting. PEG-linked dimers
13c–e, which had proven to be the most active from the in vitro
studies, were injected intravenously into C57 BL/6 WT mice. Blood
serum was taken at 18 h and the presence of IFNc determined by
ELISA (Fig. 7).62 iNKT-cell stimulation was found to increase with
linker length, up to the point where the dimer with the longest
octa(ethylene glycol) linker, 13e, had almost the same activity as
Figure 7. Wildtype C57 BL/6 (n = 3/group) mice were injected intravenously with
1 lg of analogue or vehicle. IFNc levels in blood serum were determined by ELISA at
18 h post injection.62
P. J. Jervis et al. / Carbohydrate Research 356 (2012) 152–162 157a-GalCer 7. As before, CD1d/ (iNKT cell-deﬁcient) mice did not
have any detectable IFNc (data not shown), indicating that these
results are again CD1d-dependent. These in vivo results raise the
question of how this trend of iNKT-cell stimulation versus linker
length would extrapolate with even longer linkers.
In summary, we have synthesised two series of biologically ac-
tive dimeric a-GalCer analogues (13a–e and 14a–c). Initial in vitro
experiments showed that dimers based on poly(ethylene glycol)
linkers (13a–e) stimulated iNKT cells to a similar extent as a-GalCer
7 for longer linker lengths (13c–e), whilst thosewith shorter lengths
(13a,b) were less-effective CD1d agonists. We considered the possi-
bility that this trend might be due to the linking poly(ethylene gly-
col) unit itself rather than as a result of a bivalent effect and
therefore synthesised and tested a series of monomers (10a–e) con-
taining a poly(ethylene glycol) tail length corresponding to each di-
mer linker length. These monomers showed a similar trend to the
corresponding dimers, with 10a,b being the least active. Surpris-
ingly, monomer 10dwas more active than its corresponding dimer,
13d. Dimers based on alkylene linkers proved to be less active than
a-GalCer 7 in vitro, and showed no obvious sensitivity to linker
length. Overall, the in vitro results show little evidence for a bivalent
effect. Preliminary in vivo experiments show an increase in activity
with increasing linker length, with the octa(ethylene glycol)-linked
dimer 13e being the most potent activator of iNKT cells, having a
similar activity to a-GalCer 7. Future work will involve producing
dimers and multimers with longer linker lengths and further prob-
ing the multivalent effects using different techniques.
4. Experimental
4.1. General methods
Infra-red spectra were recorded neat as thin ﬁlms between so-
dium chloride discs, or as potassium bromide discs. The intensity
of each band is described as s (strong), m (medium) or w (weak)
and with the preﬁx v (very) and sufﬁx br (broad) where appropri-
ate. The poor solubility of all a-GalCer dimers at rt prevented us
from obtaining reliable optical rotation data. 1H NMR and 13C
NMR chemical shifts are reported as d values (ppm) referenced to
the following solvent signals: CHCl3, dH 7.26; CDCl3, dC 77.0; MeOH,
dH 3.31; CD3OD, dC 49.0. The term ‘stack’ is used to describe a
region where resonances arising from non-equivalent nuclei are
coincident, and multiplet, m, to describe a resonance arising from
a single nucleus (or equivalent nuclei) but where couplingconstants cannot be readily assigned. Mass spectra were recorded
on a LCT spectrometer utilising electrospray ionisation with a
methanol mobile phase, or electron impact ionisation, and are re-
ported as (m/z (%)). HRMS were recorded on a LCT spectrometer
using a lock mass incorporated into the mobile phase. Melting
points were determined using open capillaries and are
uncorrected.
4.2. Chemicals
All reagents were obtained from commercial sources and used
without further puriﬁcation unless speciﬁed otherwise. Tetrahy-
drofuran was freshly distilled under nitrogen from sodium benzo-
phenone ketyl. All solutions are aqueous and saturated unless
speciﬁed otherwise.
4.3. General procedures
4.3.1. General procedure for bis-propargylation of diols 15a–d
and mono-propargylation of alcohols 19a–d (synthesis of
diynes 16b–e and alkynes 9b–e)
NaH (60% w/w in mineral oil, 3 equiv (for bis-propargylation) or
1.5 equiv (for mono-propargylation)) was added to a solution of
appropriate diol 15ba–d or alcohol 19a–d (1 equiv) in anhydrous
THF (0.2 M) at 0 C under an N2 atmosphere. A catalytic amount
(spatula tip) of Bu4NI (0.05 equiv) and propargyl bromide (3 equiv
(for bis-propargylation) or 1.5 equiv (for mono-propargylation))
was added sequentially. The mixture was stirred at rt overnight,
before being concentrated under reduced pressure. Puriﬁcation of
the residue by ﬂash column chromatography afforded diynes
16b–e and alkynes 9b–e as pale yellow oils.
4.3.2. General procedure for lithium acetylide addition to
dibromoalkanes 17a and 17b (synthesis of diynes 18b and 18c)
Lithium acetylide–ethylenediamine complex (2 equiv) was
added to a solution of dibromoalkane 17a or 17b (1 equiv) in
DMSO (0.2 M) at 0 C. The mixture was allowed to warm to rt
and stirred overnight. H2O (5  volume) and hexane (5  volume)
were added and the phases were separated. The aqueous phase
was extracted with hexane (5  volume). The combined organic
extracts were washed with brine (5  volume), dried (MgSO4), ﬁl-
tered and concentrated under reduced pressure. Puriﬁcation of the
residue by ﬂash column chromatography (hexane) afforded diyne
18b or 18c both as white solids.
4.3.3. General procedure for click chemistry (synthesis of
dimers 13a–e and 14a–c and monomers 10a–e and 12)
CuSO4 solution (5 lL of 0.5 M solution, 2.5 lmol) and sodium
ascorbate solution (18 lL of a 1.0 M solution, 18 lmol) were added
to a solution of azide 8 (20 mg, 0.023 mmol) and diyne 14a–e or
16a–c (0.011 mmol) or alkyne 9a–e or 11 (0.023 mmol) in
tBuOH/H2O (1 mL, 1:1) at rt. The reaction mixture was heated for
10 h at 50 C and then diluted with CHCl3 (10 mL), and washed
with brine (3 mL). The phases were separated and the aqueous
layer was extracted with CHCl3 (2  5 mL). The combined organic
layers were dried over MgSO4, ﬁltered and concentrated under re-
duced pressure. Puriﬁcation of the residue by ﬂash column chro-
matography afforded dimers 13a–e and 14a–c and monomers
10a–e and 12.
4.4. Characterisation
4.4.1. Bis-O-propargyl-di(ethylene glycol) (16b)
Diyne 16b was prepared from di(ethylene glycol) 15a (1.00 g,
9.43 mmol) and propargyl bromide (2.54 mL of a 80% w/w solution
in toluene, 29.5 mmol) according to Section 4.3.1. After stirring
158 P. J. Jervis et al. / Carbohydrate Research 356 (2012) 152–162overnight, removal of the solvent and puriﬁcation of the residue by
ﬂash column chromatography (25% EtOAc in hexane) afforded
diyne 16b as a yellow oil (1.38 g, 81%): Rf = 0.28 (25% EtOAc in hex-
ane); IR (ﬁlm) m 3252m („C–H), 2866m, 2114w (C„C), 1443m,
1349m, 1288w, 1136s, 1094s, 1033m, 918m, 877w, 843m; 1H
NMR (300 MHz, CDCl3) d 2.42 (t, 2H, J 2.4 Hz), 3.65–3.73 (stack,
8H, OCH2CH2O), 4.19 (d, 4H, J 2.4 Hz); 13C NMR: (75 MHz, CDCl3)
d 58.1 (CH2), 68.9 (CH2), 70.2 (CH2), 74.4 (CH), 79.4 (quat. C); m/z
(TOF ES+) 205.1 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 205.0847.
C10H14NaO3 requires 205.0841.
4.4.2. Bis-O-propargyl-tri(ethylene glycol) (16c)
Diyne 16c was prepared from tri(ethylene glycol) 15b (1.42 g,
9.47 mmol) and propargyl bromide (2.54 mL of a 80% w/w solution
in toluene, 29.5 mmol) according to Section 4.3.1. After stirring
overnight, removal of the solvent and puriﬁcation of the residue
by ﬂash column chromatography (40% EtOAc in hexane) afforded
diyne 16c as a yellow oil (1.52 g, 71%): Rf = 0.31 (40% EtOAc in hex-
ane); IR (ﬁlm) m 3251m („C–H), 2868m, 2114w (C„C), 1443m,
1349m, 1248m, 1093s, 1031s, 917s, 877s, 842s, 731s; 1H NMR
(300 MHz, CDCl3) d 2.43 (t, 2H, J 2.4 Hz), 3.65–3.78 (12H, stack),
4.21 (d, 4H, J 2.4 Hz); 13C NMR (75 MHz, CDCl3) d 58.2 (CH2,),
68.9 (CH2), 70.2 (CH2), 70.4 (CH2), 74.4 (CH), 79.5 (quat. C); m/z
(TOF ES+) 249.1 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 249.1094.
C12H18NaO4 requires 249.1103.
4.4.3. Bis-O-propargyl-penta(ethylene glycol) (16d)
Diyne 16d was prepared from penta(ethylene glycol) 15c
(2.25 g, 9.45 mmol) and propargyl bromide (2.54 mL of 80% w/w
solution in toluene, 29.5 mmol) according to Section 4.3.1. After
stirring overnight, removal of the solvent and puriﬁcation of the
residue by ﬂash column chromatography (60% EtOAc in hexane)
afforded diyne 16d as a yellow oil (2.17 g, 73%): Rf = 0.26 (60%
EtOAc in hexane); IR (ﬁlm) m 3247m („C–H), 2867s, 2113w
(C„C), 1458m, 1349m, 1289m, 1248m, 1093s, 1032s, 948m,
919m, 842m, 669s; 1H NMR (300 MHz, CDCl3) d 2.43 (t, 2H, J
2.4 Hz), 3.64–3.73 (stack, 20H), 4.20 (d, 4H, J 2.4 Hz); 13C NMR
(75 MHz, CDCl3) d 58.3 (CH2), 69.1 (CH2), 70.3 (CH2), 70.5 (CH2),
74.5 (CH), 79.6 (quat. C), some overlapping ethylene glycol reso-
nances; m/z (TOF ES+) 337.2 ([M+Na]+, 100%); HRMS m/z (TOF
ES+) 337.1615. C16H26NaO6 requires 337.1627.
4.4.4. Bis-O-propargyl-octa(ethylene glycol) (16e)
Diyne 16e was prepared from octa(ethylene glycol) 15d (1.00 g,
2.70 mmol) and propargyl bromide (0.73 mL of a 80% w/w solution
in toluene, 8.20 mmol) according to Section 4.3.1. After stirring
overnight, removal of the solvent and puriﬁcation of the residue
by ﬂash column chromatography (6% MeOH in CHCl3) afforded
diyne 16e as a yellow oil (1.03 g, 85%): Rf = 0.29 (6% MeOH in
CHCl3); IR (ﬁlm) m 3247m („C–H), 2919m, 2864m, 2112w
(C„C), 1956w, 1458m, 1349m, 1291m, 1248m, 1093s, 1032m,
946m, 840m, 703m, 688m, 675m, 660m; 1H NMR (300 MHz,
CDCl3) d 2.43 (t, 2H, J 2.4 Hz), 3.64–3.73 (stack, 32H), 4.20 (d, 4H,
J 2.4 Hz); 13C NMR (75 MHz, CDCl3) d 58.2 (CH2), 68.9 (CH2), 70.1
(CH2), 70.3 (CH2), 74.4 (CH), 79.5 (quat. C), some overlapping eth-
ylene glycol resonances; m/z (TOF ES+) 469.2 ([M+Na]+, 100%);
HRMS m/z (TOF ES+) 469.2406. C22H38NaO9 requires 469.2414.
4.4.5. Hexadeca-1,15-diyne (18b)
Lithium acetylide–ethylenediamine complex (693 mg,
7.50 mmol) and dibromide 17a (1.15 g, 3.51 mmol) were reacted
according to Section 4.3.2. After stirring overnight, work-up and
puriﬁcation of the residue by ﬂash column chromatography (hex-
ane) afforded diyne 18b as a white solid (62%): mp 43–45 C,
lit.63 43–44 C; Rf = 0.65 (hexane); IR (KBr) m 3286m („C–H),
2917m, 2849m, 2115w (C„C), 1472m, 1462m, 1419w, 1339w,1280w, 732m, 720m, 666s; 1H NMR (300 MHz, CDCl3) d 1.13–
1.44 (stack, 16H), 1.46–1.57 (m, 4H), 1.93 (t, 2H, J 2.6 Hz), 2.17
(td, 4H, J 6.9, 2.6 Hz); 13C NMR (75 MHz, CDCl3) d [18.4, 28.5,
28.8, 29.1, 29.5, 29.6 (CH2, overlapping alkyl chain resonances)],
68.0 (CH, C„CH), 84.8 (quat. C, C„CH); m/z (TOF ES+) 241.2
([M+Na]+, 100%); HRMSm/z (TOF ES+) 241.1941. C16H26Na requires
241.1932.
4.4.6. Docosa-1,21-diyne (18c)
Lithium acetylide–ethylenediamine complex (36mg, 0.39 mmol)
anddibromide17b (75 mg, 0.18 mmol)were reacted according to Sec-
tion 4.3.2. After stirring overnight,work-up and puriﬁcation of the res-
idue by ﬂash column chromatography (hexane) afforded diyne 18c as
awhite solid (58%):mp64–65 C;Rf = 0.73 (hexane); IR (KBr) m 3906m
(„C–H), 2917m, 2849m, 2115w (C„C), 1472m, 1462m, 1419w,
1340w, 1280w, 733m, 720m, 665s; 1H NMR (300MHz, CDCl3) d
1.17–1.45 (stack, 28H), 1.46–1.57 (m, 4H), 1.93 (t, 2H, J 2.6 Hz), 2.18
(td, 4H, J 7.1, 2.6 Hz); 13C NMR (75 MHz, CDCl3) d [18.4, 28.5, 28.8,
29.1, 29.5, 29.7 (CH2, overlapping alkyl chain resonances)], 68.0 (CH),
84.8 (quat. C); m/z (TOF ES+) 325.3 ([M+Na]+, 100%); HRMS m/z (TOF
ES+) 325.2867. C22H38Na requires 325.2871.4.4.7. Bis-1,2,3-triazole 13a (PEG-0 link)
Azide 8 (20 mg, 0.023 mmol) and diyne 16a (1.0 mg,
0.011 mmol) were reacted according to Section 4.3.3. After 10 h,
work-up and puriﬁcation of the residue by ﬂash column chroma-
tography (15% MeOH in CHCl3) afforded bis-1,2,3-triazole 13a as
a colourless paste (15 mg, 72%): Rf = 0.22 (15% MeOH in CHCl3);
IR (KBr) m 3353br s (O–H), 2917s, 2850s, 1638m (C@O), 1544w,
1468m, 1343w, 1230w, 1148m, 1066s, 1035s, 784w, 720s; 1H
NMR (300 MHz, CDCl3/CD3OD, 2:1) d 0.85 (app. t, 12H, J 6.6 Hz),
1.14–1.36 (stack, 136H), 1.42–1.63 (stack, 8H), 2.14 (app. t, 4H,
J 6.7 Hz), 3.36–3.40 (m, 2H), 3.45–3.52 (stack, 6H), 3.71 (dd, 2H,
J 9.9, 3.0 Hz), 3.75–3.83 (stack, 4H), 4.03–4.12 (m, 2H), 4.16
(app. t, 2H, J 5.7 Hz), 4.53–4.62 (stack, 8H), 4.86 (d, 2H, J
3.6 Hz), 7.89 (br s, 2H), exchangeable protons not observed; 13C
NMR (75 MHz, CDCl3/CD3OD, 2:1) d 13.5 (CH3), [20.6, 22.2, 25.4,
28.79. 28.85, 28.92, 29.1, 29.2, 31.4, 31.9, 35.9 (CH2, overlapping
alkyl chain resonances)], 49.6 (CH), 50.5 (CH2), 62.6 (CH2), 66.6
(CH), 68.1 (CH), 68.9 (2  CH, resonance overlap), 69.4 (CH2),
71.4 (CH), 74.0 (CH), 99.1 (CH), 124.5 (CH), 144.9 (quat. C),
174.0 (quat. C); m/z (TOF ES) 1859.3 ([MH], 100%), 1691.0
(43), 1521.7 (63).4.4.8. Bis-1,2,3-triazole 13b (PEG-2 link)
Azide 8 (20 mg, 0.023 mmol) and diyne 16b (2.0 mg,
0.011 mmol) were reacted according to Section 4.3.3. After 10 h,
work-up and puriﬁcation of the residue by ﬂash column chroma-
tography (15% MeOH in CHCl3) afforded bis-1,2,3-triazole 13b as
a colourless paste (18 mg, 84%): Rf = 0.23 (15% MeOH in CHCl3);
IR (KBr) m 3351m br (O–H), 2917s, 2850s, 1631m (C@O), 1547w,
1467m, 1349w, 1230w, 1141m, 1064s, 1034s, 785w, 720s; 1H
NMR (300 MHz, CDCl3/CD3OD, 2:1) d 0.84 (app. t, 12H, J 6.6),
1.14–1.32 (stack, 136H), 1.46–1.61 (stack, 8H), 2.14 (app. t, 4H, J
6.7 Hz), 3.32–3.40 (m, 2H), 3.41–3.50 (stack, 6H), 3.61–3.73 (stack,
10H), 3.75–3.83 (stack, 4H), 4.04–4.12 (m, 2H), 4.18 (dt, 2H, J 3.3,
3.0 Hz), 4.52–4.59 (stack, 4H), 4.60–4.66 (stack, 4H), 4.85 (d, 2H, J
3.6 Hz), 7.84 (br d, 2H, J 3.0 Hz), exchangeable protons not ob-
served; 13C NMR (75 MHz, CDCl3/CD3OD, 2:1) d 13.5 (CH3), [20.6,
22.2, 25.5, 28.9, 29.0, 29.1, 29.2, 29.3, 29.3, 29.4, 29.8, 31.5, 32.2,
33.8, 36.1 (CH2, overlapping alkyl chain resonances)], 49.7 (CH),
50.4 (CH2), 63.8 (CH2), 66.9 (CH2), 68.3 (CH), 68.9 (CH), 69.0 (CH),
69.2 (CH2), 69.5 (CH), 70.0 (CH2), 71.6 (CH), 74.2 (CH), 99.2 (CH),
124.4 (CH), 144.8 (quat. C), 174.0 (quat. C); m/z (TOF ES+) 1947.9
([M+H]+, 80%), 1107.9 (42), 1025.9 (100).
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Azide 8 (20 mg, 0.023 mmol) and diyne 16c (2.5 mg,
0.011 mmol) were reacted according to Section 4.3.3. After 10 h,
work-up and puriﬁcation of the residue by ﬂash column chroma-
tography (15% MeOH in CHCl3) afforded bis-1,2,3-triazole 13c as
a colourless paste (19 mg, 87%): Rf = 0.23 (15% MeOH in CHCl3);
IR (KBr) m 3368m br (O–H), 2918s, 2850s, 1634m (C@O), 1552w,
1467s, 1349w, 1231w, 1147m, 1071s, 1037s, 785w, 719m; 1H
NMR (400 MHz, CDCl3/CD3OD, 2:1) d 0.85 (app. t, 12H, J 6.6 Hz),
1.15–1.33 (stack, 136H), 1.45–1.62 (stack, 8H), 2.14 (app. t, 4H, J
7.2 Hz), 3.36–3.43 (m, 2H), 3.43–4.52 (stack, 6H), 4.53–3.60 (m,
2H), 3.60–3.73 (stack, 14H), 3.76–3.81 (m, 2H), 4.06–4.11 (m,
2H), 4.18 (app. t, 2H, J 6.0 Hz), 4.55–4.59 (stack, 4H), 4.60–4.64
(stack, 4H), 4.85 (d, 2H, J 3.6 Hz), 7.84 (br s, 2H), exchangeable pro-
tons not observed; 13C NMR (100 MHz, CDCl3/CD3OD, 2:1) d 13.3
(CH3), [22.1, 25.4, 28.7, 28.82, 28.88, 28.93, 29.1, 29.3, 31.4, 31.9,
35.9 (CH2, overlapping alkyl chain resonances)], 49.6 (CH), 50.4
(CH2), 63.6 (CH2), 66.6 (CH2), 68.2 (CH), 68.9 (CH), 69.0 (CH), 69.1
(CH2), 69.4 (CH), 69.8 (CH2), 69.9 (CH2), 71.4 (CH), 74.0 (CH), 99.1
(CH), 124.3 (CH), 144.3 (quat. C), 173.9 (quat. C); m/z (TOF ES+)
1992.0 ([M+H]+, 30%), 1070.0 (100).4.4.10. Bis-1,2,3-triazole 13d (PEG-5 link)
Azide 8 (20 mg, 0.023mmol) and diyne 16d (3.5 mg, 0.011mmol)
were reacted according to Section 4.3.3. After 10 h, work-up and puri-
ﬁcation of the residue by ﬂash column chromatography (20%MeOH in
CHCl3) afforded bis-1,2,3-triazole 13d as a colourless paste (18mg,
79%): Rf = 0.23 (20% MeOH in CHCl3); IR (KBr) m 3369m br (O–H),
2918s, 2850s, 1634m (C@O), 1552w, 1467s, 1349w, 1231w, 1147m,
1070s, 1035s, 785w, 719m; 1H NMR (300MHz, CDCl3/CD3OD, 2:1) d
0.85 (app. t, 12H, J 6.8 Hz), 1.14–1.39 (stack, 136H), 1.47–1.65 (stack,
8H), 2.14 (app. t, 4H, J 7.5 Hz), 3.36–3.43 (m, 2H), 3.44–3.53 (stack,
6H), 3.60–3.67 (stack, 20H), 3.71 (dd, 2H, J 9.9, 3.3 Hz), 3.76–3.83
(stack, 4H,), 4.03–4.13 (m, 2H), 4.17 (app. t, 2H, J 6.5 Hz), 4.53–4.63
(stack, 8H), 4.86 (d, 2H, J3.6 Hz), 7.42 (d, 2H, J8.7 Hz), 7.84 (s, 2H), alco-
holic protons not observed; 13C NMR (100MHz, CDCl3/CD3OD, 2:1) d
13.2 (CH3), [22.1, 25.3, 28.78, 28.83, 28.9, 29.1, 29.09, 29.13, 31.4,
31.8, 35.8 (CH2, overlapping alkyl chain resonances)], 49.6 (CH), 50.4
(CH2), 63.5 (CH2), 66.6 (CH2), 68.1 (CH), 68.9 (CH), 69.0 (CH), 69.4
(CH), 69.8 (CH2, overlapping ethylene glycol resonances), 71.4 (CH),
73.9 (CH), 99.1 (CH), 124.3 (CH), 144.1 (quat. C), 173.9 (quat. C); m/z
(TOF ES+) 2079.2 ([M+Na]+, 100%), 694.5 (70, [ceramide]+).
4.4.11. Bis-1,2,3-triazole 13e (PEG-8 link)
Azide 8 (20 mg, 0.023 mmol) and diyne 16e (4.9 mg,
0.011 mmol) were reacted according to Section 4.3.3. After 10 h,
work-up and puriﬁcation of the residue by ﬂash column chroma-
tography (20% MeOH in CHCl3) afforded bis-1,2,3-triazole 13e as
a colourless paste (21 mg, 86%): Rf = 0.25 (20% MeOH in CHCl3);
IR (KBr) m 3340m br (O–H), 2917s, 2850s, 1632m (C@O), 1549w,
1467m, 1349m, 1300w, 1232w, 1138m, 1082s, 1039s, 948m,
786m, 719s; 1H NMR (300 MHz, CDCl3/CD3OD, 2:1) d 0.85 (app. t,
12H, J 6.9 Hz), 1.14–1.49 (stack, 136H), 1.43–1.67 (stack, 8H),
2.14 (app. t, 4H, J 7.2 Hz), 3.36–3.52 (stack, 8H), 3.60–3.68 (stack,
32H), 3.68–3.75 (m, 2H), 3.76–3.83 (stack, 4H), 4.01–4.09 (m,
2H), 4.17 (app. t, 2H, J 6.2 Hz), 4.52–4.63 (stack, 8H), 4.85 (d, 2H,
J 2.4 Hz), 7.51 (d, 2H, J 8.1 Hz), 7.83 (s, 2H), alcoholic protons not
observed; 13C NMR (100 MHz, CDCl3/CD3OD, 2:1) d 13.3 (CH3),
[22.1, 25.4, 28.8, 28.89, 28.94, 29.06, 29.13, 29.2, 29.3, 31.4, 31.9,
35.9 (CH2, overlapping alkyl chain resonances)], 49.7 (CH), 50.5
(CH2), 63.6 (CH2), 66.6 (CH2), 68.2 (CH), 68.9 (CH), 69.0 (CH), 69.4
(CH), [69.6, 69.7 (CH2, overlapping ethylene glycol resonances)]
71.4 (CH), 73.9 (CH), 99.1 (CH), 124.3 (CH), 144.8 (quat. C), 173.9
(quat. C); m/z (TOF ES+) 2211.6 ([M+H]+, 45%), 694.6 (35, [cera-
mide]+), 450.2 (100).4.4.12. Bis-1,2,3-triazole 14a (–(CH2)4 link)
Azide 8 (20 mg, 0.023 mmol) and diyne 18a (1.2 mg,
0.011 mmol) were reacted according to Section 4.3.3. After 10 h,
work-up and puriﬁcation of the residue by ﬂash column chroma-
tography (15% MeOH in CHCl3) afforded bis-1,2,3-triazole 14a as
a colourless paste (16 mg, 81%): Rf = 0.24 (15% MeOH in CHCl3);
IR (KBr) m 3359m br (O–H), 2921s, 2849s, 1636m (C@O), 1555m,
1468s, 1351w, 1222w, 1150m, 1057s, 904w, 787m, 724s; 1H
NMR (300 MHz, CDCl3/CD3OD, 2:1) d 0.84 (app. t, 12H, J 6.7 Hz),
1.14–1.38 (stack, 136H), 1.45–1.72 (stack, 12H), 2.14 (app. t, 4H, J
7.5 Hz), 2.63–2.74 (m, 4H, J 7.2 Hz), 3.38 (dd, 2H, J 10.6, 4.17 Hz),
3.43–3.58 (stack, 6H), 3.66–3.72 (m, 2H), 3.73–3.82 (stack, 4H),
4.07–4.20 (stack, 4H), 4.48–4.57 (stack, 4H), 4.85 (d, 2H, J 3.6 Hz),
7.41 (d, 2H, J 8.8 Hz), 7.56 (s, 2H), alcoholic protons not observed;
13C NMR (75 MHz, CDCl3/CD3OD, 2:1) d 13.4 (CH3), [22.2, 24.5,
25.3, 25.4, 25.5, 28.2, 28.9, 28.96, 29.02, 29.2, 29.3, 29.4, 31.5,
32.2, 36.0 (CH2, overlapping alkyl chain resonances)], 49.7 (CH),
50.2 (CH2), 66.8 (CH2), 68.2 (CH), 68.8 (CH), 69.0 (CH), 69.5 (CH),
71.5 (CH), 74.3 (CH), 99.2 (CH), 122.6 (CH), 147.5 (quat. C), 174.0
(quat. C); m/z (TOF ES+) 1894.5 ([M+Na]+, 100%).
4.4.13. Bis-1,2,3-triazole 14b (–(CH2)12 link)
Azide 8 (20 mg, 0.023 mmol) and diyne 18b (2.1 mg, 0.011mmol)
were reacted according to Section 4.3.3. After 10 h, work-up and puri-
ﬁcation of the residue by ﬂash column chromatography (15%MeOH in
CHCl3) afforded bis-1,2,3-triazole 14b as a colourless paste (19mg,
88%): Rf = 0.26 (15% MeOH in CHCl3); IR (KBr) m 3351m br (O–H),
2917s, 2850s, 1635m (C@O), 1550m, 1467s, 1344w, 1221w, 1150m,
1058s, 906w, 784m, 720m; 1H NMR (300MHz, CDCl3/CD3OD, 2:1) d
0.85 (app. t, 12H, J 6.6 Hz), 1.15–1.49 (stack, 152H), 1.47–1.68 (stack,
12H), 2.14 (app. t, 4H, J 7.5 Hz), 2.65 (app. t, 4H, J 7.2 Hz), 3.36–3.43
(m, 2H), 3.44–3.55 (stack, 6H), 3.67–3.74 (m, 2H), 3.76–3.83 (stack,
4H), 4.07–4.21 (stack, 4H), 4.47–4.60 (stack, 4H), 4.86 (d, 2H, J
3.3 Hz), 7.56 (s, 2H), exchangeable protons not observed; 13C NMR
(100MHz, CDCl3/CD3OD, 2:1) d 13.1 (CH3), [22.0, 24.8, 25.2, 25.3,
28.7, 28.76, 28.83, 29.0, 29.1, 29.2, 31.3, 35.8 (CH2, overlapping alkyl
chain resonances)], 49.5 (CH), 50.2 (CH2), 66.4 (CH2), 68.1 (CH), 68.9
(CH), 69.0 (CH), 69.4 (CH), 71.3 (CH), 74.0 (CH), 99.0 (CH), 122.3
(CH), 147.6 (quat. C), 174.0 (quat. C); m/z (TOF ES) 1983.1 ([MH]
100%).
4.4.14. Bis-1,2,3-triazole 14c (–(CH2)18 link)
Azide 8 (20 mg, 0.023 mmol) and diyne 18c (3.3 mg,
0.011 mmol) were reacted according to Section 4.3.3. After 10 h,
work-up and puriﬁcation of the residue by ﬂash column chroma-
tography (15% MeOH in CHCl3) afforded bis-1,2,3-triazole 14c as
a colourless paste (20 mg, 87%): Rf = 0.27 (15% MeOH in CHCl3);
IR (ﬁlm) m 3386m br (O–H), 2918s, 2851s, 1637m (C@O), 1537w,
1467s, 1438w, 1345w, 1204m, 1151s, 1065s, 1036s, 801m, 720s;
1H NMR (300 MHz, CDCl3/CD3OD, 2:1) d 0.85 (app. t, 12H, J
6.6 Hz), 1.14–1.49 (stack, 164H), 1.47–1.68 (stack, 12H), 2.14
(app. t, 4H, J 7.7 Hz), 2.65 (app. t, 4H, J 7.5 Hz), 3.38 (dd, 2H, J
10.2, 4.2 Hz), 3.43–3.55 (stack, 6H), 3.69 (dd, 2H, J 10.2, 3.0 Hz),
3.76–3.82 (stack, 4H), 4.07–4.20 (stack, 4H), 4.45–4.60 (stack,
4H), 4.87 (d, 2H, J 3.6 Hz), 7.54 (br s, 2H), exchangeable protons
not observed; 13C NMR (100 MHz, CDCl3/CD3OD, 2:1) d 13.2
(CH3), [22.1, 24.8, 25.28, 25.32, 28.77, 28.82, 28.87, 28.92, 29.00,
29.09, 29.13, 29.3, 31.4, 32.0, 35.8 (CH2, overlapping alkyl reso-
nances)], 49.6 (CH), 50.2 (CH2), 66.4 (CH2), 68.1 (CH), 68.9 (CH),
69.0 (CH), 69.4 (CH), 71.3 (CH), 74.1 (CH), 99.1 (CH), 122.2 (CH),
147.7 (quat. C), 173.8 (quat. C); m/z (TOF ES+) 2067.7 ([M+Na]+,
30%), 1885.3 (30), 694.6 (100, [ceramide]+).
4.4.15. O-Propargyl-O0-methyl-di(ethylene glycol) (9b)
Alkyne 9b was prepared from di(ethylene glycol) monomethyl
ether (19a) (0.50 g, 4.16 mmol) and propargyl bromide (0.53 mL
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4.3.1. After stirring overnight, removal of the solvent and puriﬁca-
tion of the residue by ﬂash column chromatography (25% EtOAc in
hexane) afforded alkyne 9b as a yellow oil (0.57 g, 87%): Rf = 0.26
(25% EtOAc in hexane); IR (ﬁlm) m 3251m („C–H), 2866m,
2113w (C„C), 1442m, 1350m, 1295w, 1288w, 1136s, 1094s,
1033m, 918m, 877w, 843m, 734m; 1H NMR (300 MHz, CDCl3) d
2.41 (t, 1H, J 2.4 Hz), 3.35 (s, 3H), 3.50–3.58 (m, 2H), 3.59–3.72
(stack, 6H), 4.17 (d, 2H, J 2.4 Hz); 13C NMR (75 MHz, CDCl3) d
58.3 (CH), 58.9 (CH3), 69.0 (CH2), 70.3 (CH2), 70.5 (CH2), 71.8
(CH2), 74.4 (CH), 79.6 (quat. C); m/z (TOF ES+) 181.1 ([M+Na]+,
100%); HRMS m/z (TOF ES+) 181.0837. C10H18NaO3 requires
181.0841.
4.4.16. O-Propargyl-O0-methyl-triethylene glycol (9c)
Alkyne 9c was prepared from tri(ethylene glycol) monomethyl
ether (19b) (250 mg, 1.52 mmol) and propargyl bromide (190 lL
of a 80% w/w solution in toluene, 2.28 mmol) according to Section
4.3.1. After stirring overnight, removal of the solvent and puriﬁca-
tion of the residue by ﬂash column chromatography (40% EtOAc in
hexane) afforded alkyne 9c as a yellow oil (279 mg, 91%): Rf = 0.30
(40% EtOAc in hexane); IR (ﬁlm) m 3248m („C–H), 2865m, 2114w
(C„C), 1442m, 1348m, 1246m, 1092s, 1031s, 918s, 879s, 842s,
756m, 731s; 1H NMR (300 MHz, CDCl3) d 2.41 (t, 1H, J 2.4 Hz),
3.35 (s, 3H), 3.50–3.59 (m, 2H), 3.59–3.74 (stack, 10H), 4.17 (d,
2H, J 2.4 Hz); 13C NMR (75 MHz, CDCl3) d 58.3 (CH), 58.9 (CH3),
69.0 (CH2), 70.3 (CH2), 70.4 (CH2), 70.5 (CH2, overlapping ethylene
glycol resonances), 71.8 (CH2), 74.4 (CH), 79.6 (quat. C); m/z (TOF
ES+) 225.1 ([M+Na]+, 100%); HRMS m/z (TOF ES+) 225.1110.
C10H18NaO4 requires 225.1103.
4.4.17. O-Propargyl-O0-methyl-penta(ethylene glycol) (9d)
Alkyne 9d was prepared from penta(ethylene glycol) mono-
methyl ether (19c) (250 mg, 0.99 mmol) and propargyl bromide
(126 lL of a 80% w/w solution in toluene, 1.49 mmol) according
to Section 4.3.1. After stirring overnight, removal of the solvent
and puriﬁcation of the residue by ﬂash column chromatography
(60% EtOAc in hexane) afforded alkyne 9d as a yellow oil
(244 mg, 85%): Rf = 0.24 (60% EtOAc in hexane); IR (ﬁlm) m
3253m („C–H), 2869m, 2113w (C„C), 1447m, 1346m, 1247m,
1093s, 1029s, 917s, 879s, 842s, 748m, 731s; 1H NMR (300 MHz,
CDCl3) d 2.42 (t, 1H, J 2.4 Hz), 3.36 (s, 3H), 3.50–3.58 (m, 2H),
3.60–3.73 (stack, 18H), 4.18 (d, 2H, J 2.4 Hz); 13C NMR (75 MHz,
CDCl3) d 58.3 (CH), 59.0 (CH3), 69.0 (CH2), 70.3 (CH2), 70.45
(CH2), 70.51 (CH2, overlapping ethylene glycol resonances), 71.9
(CH2), 74.4 (CH), 79.6 (quat. C); m/z (TOF ES+) 313.3 ([M+Na]+,
100%); HRMS m/z (TOF ES+) 313.1624. C14H26NaO6 requires
313.1627.
4.4.18. O-Propargyl-O0-methyl-octa(ethylene glycol) (9e)
Alkyne 9e was prepared from octa(ethylene glycol) mono-
methyl ether (19d) (100 mg, 0.26 mmol) and propargyl bromide
(32 lL of a 80% w/w solution in toluene, 0.39 mmol) according to
Section 4.3.1. After stirring overnight, removal of the solvent and
puriﬁcation of the residue by ﬂash column chromatography (5%
MeOH in CHCl3) afforded alkyne 9e as a yellow oil (244 mg,
85%): Rf = 0.23 (5% MeOH in CHCl3); IR (ﬁlm) m 3248m („C–H),
2916m, 2864m, 2114w (C„C), 1956w, 1457m, 1346m, 1292m,
1246m, 1094s, 1030m, 946m, 839m, 764m, 703m; 1H NMR
(300 MHz, CDCl3) d 2.41 (t, 1H, J 2.4 Hz), 3.32 (s, 3H), 3.46–3.54
(m, 2H), 3.57–3.70 (stack, 30H), 4.15 (d, 2H, J 2.4 Hz); 13C NMR
(75 MHz, CDCl3) d 58.2 (CH), 58.8 (CH3), 68.9 (CH2), 70.2 (CH2),
70.4 (CH2, some overlapping ethylene glycol resonances), 71.8
(CH2), 74.4 (CH), 79.5 (quat. C); m/z (TOF ES+) 445.2 ([M+Na]+,
100%); HRMS m/z (TOF ES+) 445.2421. C20H38NaO9 requires
445.2414.4.4.19. 1,2,3-triazole 10a (PEG-0 tail)
Azide 8 (20 mg, 0.023 mmol) and alkyne 9a (1.6 mg,
0.023 mmol) were reacted according to Section 4.3.3. After 10 h,
work-up and puriﬁcation of the residue by ﬂash column chroma-
tography (15% MeOH in CHCl3) afforded 1,2,3-triazole 10a as a col-
ourless paste (20 mg, 92%): Rf = 0.29 (15% MeOH in CHCl3); IR (KBr)
m 3352br s (O–H), 2914s, 2851s, 1638m (C@O), 1543w, 1467m,
1343w, 1229w, 1150m, 1067s, 1034s, 784w, 720s, 717w, 668m;
1H NMR (300 MHz, CDCl3/CD3OD, 2:1) d 0.84 (app. t, 6H, J
6.6 Hz), 1.14–1.38 (stack, 68H), 1.43–1.67 (stack, 4H), 2.13 (app.
t, 2H, J 7.5 Hz), 3.33–3.40 (stack including [3.37 (s, 3H)], 4H),
3.42–3.52 (stack, 3H), 3.69 (dd, 1H, J 9.8, 3.3 Hz), 3.74–3.83 (stack,
2H), 4.03–4.13 (m, 1H), 4.13–4.20 (m, 1H), 4.52 (s, 2H), 4.53–4.59
(m, 2H), 4.85 (d, 1H, J 3.7 Hz), 7.28 (d, 1H, J 8.79 Hz), 7.78 (s, 1H),
alcoholic protons not observed; 13C NMR (75 MHz, CDCl3/CD3OD,
2:1) d 14.2 (CH3), [23.0, 26.2, 29.7, 30.0, 32.3, 33.0, 36.8 (CH2, over-
lapping alkyl resonances)], 50.5 (CH), 51.3 (CH2), 58.4 (CH3), 65.8
(CH2), 67.5 (CH2), 69.0 (CH), 69.7 (CH), 69.8 (CH), 70.3 (CH), 72.3
(CH), 75.1 (CH), 100.0 (CH), 125.0 (CH), 144.8 (quat. C), 174.7 (quat.
C); m/z (TOF ES+) 975.8 ([M+Na]+, 100%); HRMS m/z (TOF ES+)
975.7711. C54H104N4NaO9 requires 975.7701.
4.4.20. 1,2,3-triazole 10b (PEG-2 tail)
Azide 8 (20 mg, 0.023mmol) and alkyne 9b (4.2 mg, 0.023mmol)
were reacted according to Section 4.3.3. After 10 h, work-up and puri-
ﬁcation of the residue by ﬂash column chromatography (15% MeOH
in CHCl3) afforded 1,2,3-triazole 10b as a colourless paste (22mg,
94%): Rf = 0.27 (15% MeOH in CHCl3); IR (KBr) m 3347m br (O–H),
2917s, 2849s, 1632m (C@O), 1544w, 1469m, 1349w, 1347w,
1230w, 1141m, 1063s, 1036s, 785w, 732m, 720s; 1H NMR
(300MHz, CDCl3/CD3OD, 2:1) d 0.84 (app. t, 6H, J 6.6 Hz), 1.13–1.38
(stack, 68H), 1.46–1.63 (stack, 4H), 2.13 (app. t, 2H, J 7.4 Hz), 3.33–
3.39 (stack including [3.35 (s, 3H)]), 4H, 3.42–3.51 (stack, 3H),
3.51–3.55 (stack, 2H), 3.58–3.64 (stack, 6H), 3.69 (dd, 1H, J 9.6,
3.2 Hz), 3.76–3.80 (stack, 2H), 4.09 (dd, 1H, J 8.4, 4.8 Hz), 4.15–4.20
(m, 1H), 4.52–4.58 (m, 2H), 4.62 (s, 2H), 4.85 (d, 1H, J 4.0 Hz), 7.80
(s, 1H), exchangeable protons not observed; 13C NMR (75MHz,
CDCl3/CD3OD, 2:1) d 14.2 (CH3), [23.0, 26.2, 29.7, 30.0, 32.3, 33.0,
36.8 (CH2, overlapping alkyl resonances)], 50.5 (CH), 51.3 (CH2),
59.1 (CH3), 64.5 (CH2), 67.5 (CH2), 69.0 (CH), 69.7 (CH), 69.8 (CH),
70.0 (CH2), 70.3 (CH), 70.67 (CH2), 70.73 (CH2), 72.2 (CH2), 72.3
(CH), 75.0 (CH), 100.0 (CH), 125.1 (CH), 145.0 (quat. C), 174.7 (quat.
C); m/z (TOF ES+) 1064.0 ([M+Na]+, 100%); HRMS m/z (TOF ES+)
1063.8217. C58H112N4NaO11 requires 1063.8225.
4.4.21. 1,2,3-Triazole 10c (PEG-3 tail)
Azide 8 (20 mg, 0.023 mmol) and alkyne 9c (4.6 mg,
0.023 mmol) were reacted according to Section 4.3.3. After 10 h,
work-up and puriﬁcation of the residue by ﬂash column chroma-
tography (15% MeOH in CHCl3) afforded 1,2,3-triazole 10c as a col-
ourless paste (23 mg, 91%): Rf = 0.27 (15% MeOH in CHCl3); IR (KBr)
m 3368m br (O–H), 2916s, 2849s, 1630m (C@O), 1551w, 1467s,
1349w, 1232w, 1147m, 1071s, 1062w, 1035s, 786w, 720m; 1H
NMR (300 MHz, CDCl3/CD3OD, 2:1) d 0.86 (app. t, 6H, J 6.6 Hz),
1.12–1.39 (stack, 68H), 1.44–1.67 (stack, 4H), 2.13 (app. t, 2H, J
7.5 Hz), 3.33–3.41 (stack including [3.36 (s, 3H)]), 4H, 3.42–3.50
(stack, 3H), 3.50–3.56 (stack, 2H), 3.58–3.64 (stack, 10H), 3.69
(dd, 1H, J 9.6, 3.3 Hz), 3.75–3.81 (stack, 2H), 4.04–4.12 (m, 1H),
4.17 (app. t, 1H, J 6.9 Hz), 4.53–4.59 (m, 2H), 4.62 (s, 2H), 4.85 (d,
1H, J 3.9 Hz), 7.31 (d, 1H, J 9.0 Hz), 7.80 (s, 1H), alcoholic protons
not observed; 13C NMR (75 MHz, CDCl3/CD3OD, 2:1) d 14.2 (CH3),
[23.0, 26.2, 29.7, 29.8, 30.1, 32.3, 33.0, 36.8 (CH2, some overlapping
alkyl resonances)], 50.5 (CH), 51.3 (CH2), 59.1 (CH3), 64.6 (CH2),
67.5 (CH2), 69.0 (CH), 69.7 (CH), 69.8 (CH), 70.0 (CH2), 70.3 (CH),
[70.67, 70.74, 70.8 (CH2, some overlapping ethylene glycol reso-
nances)], 72.2 (CH2), 72.3 (CH), 75.0 (CH), 100.0 (CH), 125.1 (CH),
P. J. Jervis et al. / Carbohydrate Research 356 (2012) 152–162 161145.0 (quat. C), 174.7 (quat. C); m/z (TOF ES+) 1107.9 ([M+Na]+,
100%); HRMS m/z (TOF ES+) 1107.8484. C60H116N4NaO12 requires
1107.8487.
4.4.22. 1,2,3-Triazole 10d (PEG-5 tail)
Azide 8 (20 mg, 0.023 mmol) and alkyne 9d (6.7 mg,
0.023 mmol) were reacted according to Section 4.3.3. After 10 h,
work-up and puriﬁcation of the residue by ﬂash column chroma-
tography (20% MeOH in CHCl3) afforded 1,2,3-triazole 10d as a col-
ourless paste (20 mg, 87%): Rf = 0.28 (20% MeOH in CHCl3); IR (KBr)
m 3368m br (O–H), 2917s, 2848s, 1635m (C@O), 1550w, 1467s,
1348w, 1231w, 1145m, 1070s, 1035s, 1001w, 785w, 719m,
685m; 1H NMR (300 MHz, CDCl3/CD3OD, 2:1) d 0.84 (app. t, 6H, J
6.5 Hz), 1.13–1.39 (stack, 68H), 1.44–1.68 (stack, 4H), 2.13 (app. t,
2H, J 7.4 Hz), 3.33–3.41 (stack including [3.35 (s, 3H)], 4H), 3.42–
3.50 (stack, 3H), 3.50–3.55 (stack, 2H), 3.58–3.65 (stack, 18H),
3.69 (dd, 1H, J 9.6, 3.2 Hz), 3.74–3.82 (stack, 2H), 4.04–4.12 (m,
1H), 4.17 (app. t, 1H, J 6.7 Hz), 4.52–4.58 (m, 2H), 4.62 (s, 2H),
4.85 (d, 1H, J 3.6 Hz), 7.80 (s, 1H), exchangeable protons not ob-
served; 13C NMR (75 MHz, CDCl3/CD3OD, 2:1) d 14.3 (CH3), [23.0,
26.2, 29.7, 29.8, 30.1, 32.3, 32.9, 36.8 (CH2, some overlapping alkyl
resonances)], 50.5 (CH), 51.3 (CH2), 59.1 (CH3), 64.6 (CH2), 67.5
(CH2), 69.0 (CH), 69.7 (CH), 69.8 (CH), 70.0 (CH2), 70.3 (CH),
[70.66, 70.79 (CH2, some overlapping ethylene glycol resonances)],
72.2 (CH2), 72.3 (CH), 75.0 (CH), 100.0 (CH), 125.1 (CH), 145.0 (quat.
C), 174.7 (quat. C);m/z (TOF ES+) 1196.6 ([M+Na]+, 100%); HRMSm/
z (TOF ES+) 1195.9045. C64H124N4NaO14 requires 1195.9045.
4.4.23. 1,2,3-Triazole 10e (PEG-8 tail)
Azide 8 (20 mg, 0.023 mmol) and alkyne 9e (9.7 mg,
0.023 mmol) were reacted according to Section 4.3.3. After 10 h,
work-up and puriﬁcation of the residue by ﬂash column chroma-
tography (20% MeOH in CHCl3) afforded 1,2,3-triazole 10e as a col-
ourless paste (29 mg, 97%): Rf = 0.27 (20%MeOH in CHCl3); IR (Kr) m
3336m br (O–H), 2919s, 2849s, 1630m (C@O), 1549w, 1467m,
1350m, 1301w, 1231w, 1138m, 1082s, 1039s, 1012w, 948m,
786m, 719s; 1H NMR (300 MHz, CDCl3/CD3OD, 2:1) d 0.84 (app. t,
6H, J 6.6 Hz), 1.12–1.39 (stack, 68H), 1.45–1.69 (stack, 4H), 2.13
(app. t, 2H, J 7.4 Hz), 3.33–3.41 (stack including [3.35 (s, 3H)],
4H), 3.41–3.50 (stack, 3H), 3.50–3.56 (stack, 2H), 3.58–3.65 (stack,
30H), 3.69 (dd, 1H, J 10.2, 3.0 Hz), 3.74–3.81 (stack, 2H), 4.05–4.13
(m, 1H), 4.18 (app. t, 1H, J 6.6 Hz), 4.52–4.58 (m, 2H), 4.62 (s, 2H),
4.85 (d, 1H, J 3.6 Hz), 7.28 (d, 1H, J 8.7 Hz), 7.80 (s, 1H), alcoholic
protons not observed; 13C NMR (75 MHz, CDCl3/CD3OD, 2:1) d
14.2 (CH3), [23.0, 26.2, 29.7, 30.0, 32.3, 33.0, 36.8 (CH2, some over-
lapping alkyl resonances)], 50.4 (CH), 51.2 (CH2), 59.1 (CH3), 64.5
(CH2), 67.5 (CH2), 69.0 (CH), 69.7 (CH), 69.8 (CH), 70.0 (CH2), 70.3
(CH), 70.8 (CH2, some overlapping ethylene glycol resonances),
72.2 (CH2), 72.3 (CH), 75.0 (CH), 100.0 (CH), 125.1 (CH), 145.0
(quat. C), 174.7 (quat. C); m/z (TOF ES+) 1328.8 ([M+Na]+, 100%);
HRMS m/z (TOF ES+) 1327.9788. C70H136N4NaO17 requires
1327.9798.
4.4.24. 1,2,3-Triazole 12 (octyl tail)
Azide 8 (20 mg, 0.023 mmol) and 1-decyne (11) (3.3 mg,
0.023 mmol) were reacted according to Section 4.3.3. After 10 h,
work-up and puriﬁcation of the residue by ﬂash column chroma-
tography (15% MeOH in CHCl3) afforded 1,2,3-triazole 12 as a col-
ourless paste (22 mg, 95%): Rf = 0.30 (15% MeOH in CHCl3); IR
(ﬁlm) m 3385m br (O–H), 2916s, 2852s, 1635m (C@O), 1532w,
1468s, 1438w, 1345w, 1204m, 1151s, 1065s, 1036s, 801m, 732m,
725m; 1H NMR (300 MHz, CDCl3/CD3OD, 2:1) d 0.84 (app. t, 9H, J
6.6 Hz), 1.12–1.43 (stack, 80H), 1.47–1.71 (stack, 6H), 2.13 (app.
t, 2H, J 7.7 Hz), 2.64 (app. t, 2H, J 7.8 Hz), 3.37 (dd, 1H, J 10.5,
4.5 Hz), 3.42–3.55 (stack, 3H), 3.68 (dd, 1H, J 10.2, 3.0 Hz), 3.75–
3.84 (stack, 2H), 4.07–4.21 (stack, 2H), 4.51–4.57 (m, 2H), 4.86(d, 1H, J 3.6 Hz), 7.29 (d, 1H, J 8.7 Hz), 7.52 (s, 1H); 13C NMR
(75 MHz, CDCl3/CD3OD, 2:1) d 14.3 (CH3), [23.0, 25.8, 26.3, 29.7,
29.8, 30.1, 32.3, 33.0, 36.8 (CH2, some overlapping alkyl reso-
nances)], 50.4 (CH), 51.1 (CH2), 67.4 (CH2), 69.1 (CH), 69.8 (CH),
69.9 (CH), 70.3 (CH), 72.3 (CH), 75.1 (CH), 100.0 (CH), 123.17
(CH), 148.6 (quat. C), 174.7 (quat. C); m/z (TOF ES+) 1043.9
([M+Na]+, 100%); HRMS m/z (TOF ES+) 1043.8697. C60H116N4NaO8
requires 1043.8691.
4.5. Materials and methods for biology
4.5.1. Mice and reagents
C57BL/6 and CD1d/ (iNKT cell-deﬁcient) mice were used. Ani-
mal experiments were carried out under the authority of a UK
Home Ofﬁce Project License. Compounds were solubilised in
150 mM NaCl and 0.5% Tween 20 (vehicle).
4.5.2. In vitro and in vivo activation of iNKT cells
For in vitro activation of iNKT cells, 5  105 splenoctyes from
C57BL/6 and CD1d/ (iNKT cell-deﬁcient) mice were pulsed with
various concentrations of a-GalCer 7, 14a–c, 13a–e, 12, 10a–e or
vehicle for 48 h. Supernatants were removed and the presence of
IFNc determined by ELISA.29 For in vivo activation of iNKT cells,
C57 BL/6 WT or CD1d/ mice were injected intravenously (iv)
with 1 lg lipids and blood serum taken at 18 h and the presence
of IFNc determined by ELISA.33
4.5.3. Soluble human NKT TCR binding assay
Soluble iNKT TCR tetramers were prepared according to the pro-
tocol described by McCarthy et al.60 C1R-hCD1d cells were pulsed
with lipids or vehicle at various concentrations overnight and fol-
lowing washes incubated with ﬂuorescently labelled iNKT TCR tet-
ramer. iNKT TCR–CD1d–lipid complexes were detected by ﬂow
cytometry on a FACScalibur device using CellQuest software.
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